Status:
TERMINATED
Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)
Lead Sponsor:
Octapharma
Conditions:
Thrombotic Thrombocytopenic Purpura (TTP)
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Prior to the use of plasma products, thrombotic thrombocytopenic purpura (TTP) was usually a fatal condition. During plasma exchange therapy, patients need transfusion plasma that is blood group speci...
Eligibility Criteria
Inclusion
- 18 years of age and above.
- Definite diagnosis of acute thrombotic thrombocytopenic purpura (TTP).
- Thrombocytopenia.
- Diagnostic signs of microangiopathic hemolytic anemia.
Exclusion
- Congenital thrombotic microangiopathies.
- Alternative secondary cause for microangiopathy.
- Co-morbid illness limiting life expectancy to less than 3 months independent of TTP.
- Patients known to be HIV positive.
- Patients known to have lupus.
- Refusal to accept blood products.
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00411801
Start Date
May 1 2007
End Date
February 1 2008
Last Update
June 21 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Contact Octapharma for Facility Details
Centreville, Virginia, United States, 20120